Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2024

Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2024

DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chemotherapy Induced Nausea and Vomiting: Understanding

Chemotherapy Induced Nausea and Vomiting: Overview

Chemotherapy-induced nausea and vomiting (CINV) is a distressing side effect experienced by many cancer patients undergoing chemotherapy treatment. It occurs due to the toxic effects of chemotherapy drugs on the gastrointestinal tract and the central nervous system. The severity and duration of CINV can vary widely among patients, with some experiencing mild symptoms while others suffer from debilitating nausea and vomiting. These symptoms can significantly impact patients' quality of life, leading to decreased appetite, weight loss, dehydration, and disruptions in daily activities.

The underlying causes of CINV are complex and multifactorial. Chemotherapy drugs can directly stimulate areas of the brain responsible for nausea and vomiting, such as the chemoreceptor trigger zone and the vomiting center. Additionally, chemotherapy-induced damage to the lining of the gastrointestinal tract can contribute to nausea and vomiting symptoms. Individual patient factors, such as age, gender, previous history of motion sickness or nausea, and genetic variations, can also influence the susceptibility to CINV. Certain chemotherapy drugs are more likely to cause CINV than others, and the risk may vary based on the dose and schedule of administration.

Diagnosing CINV primarily involves evaluating the patient's reported symptoms and medical history. Healthcare providers will inquire about the type of chemotherapy drugs received, the dosage, and the timing of symptoms relative to treatment administration. Various assessment tools, including nausea and vomiting scales, may be used to quantify the severity of symptoms and monitor their progression over time. It's essential for healthcare providers to maintain open communication with patients regarding their symptoms to tailor treatment plans accordingly and provide appropriate support.

Treatment strategies for CINV aim to prevent or minimize symptoms, improve patients' quality of life, and ensure adherence to chemotherapy regimens. Prophylactic antiemetic medications are commonly prescribed before and after chemotherapy sessions to reduce the risk of CINV. These may include serotonin receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, and other supportive medications. Non-pharmacological interventions such as dietary modifications, acupuncture, acupressure, and relaxation techniques may also be recommended as adjunct therapies. Patient education about CINV management strategies and proactive symptom monitoring are crucial components of comprehensive care for cancer patients undergoing chemotherapy.

""Chemotherapy Induced Nausea and Vomiting - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Nausea and Vomiting pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Nausea and Vomiting treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Nausea and Vomiting commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Nausea and Vomiting collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Nausea and Vomiting R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Nausea and Vomiting.

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Chapters

This segment of the Chemotherapy Induced Nausea and Vomiting report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chemotherapy Induced Nausea and Vomiting Emerging Drugs

Fosnetupitant: Helsinn Healthcare SA

Fosnetupitant is an NK1 receptor antagonist antiemetic drug developed for the prevention of chemotherapy-induced nausea and vomiting. It is a phosphorylated pro-drug preparation (injection) of netupitant, the active component. The prevention of chemotherapy-induced nausea and vomiting is considered important in clinical practice. Taiho acquired exclusive development and marketing rights for fosnetupitant in Japan under a license agreement signed in April 2011 with Helsinn Healthcare SA and has conducted clinical trials in Japan since then. The new drug application is based on the results of a Phase III clinical trial comparing the efficacy and safety of fosnetupitant and fosaprepitant (NK1 receptor antagonist) in patients receiving highly emetogenic chemotherapy. In the trial, either fosnetupitant (235 mg) or fosaprepitant (150 mg) was administered in a single I.V. dose prior to administration of the chemotherapeutic agent, in combination with palonosetron (5-HT3 receptor antagonist) and dexamethasone. Currently, the drug is in Registration stage of its development for the treatment of chemotherapy induced nausea and vomiting.

APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. Currently the drug is in Phase II stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

CAM2047: Camurus

CAM2047 is a long-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. Currently the drug is in Phase I stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

Further product details are provided in the report……..

Chemotherapy Induced Nausea and Vomiting: Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Nausea and Vomiting drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chemotherapy Induced Nausea and Vomiting

There are approx. 8+ key companies which are developing the therapies for Chemotherapy Induced Nausea and Vomiting. The companies which have their Chemotherapy Induced Nausea and Vomiting drug candidates in the most advanced stage, i.e. phase III include, Helsinn Healthcare SA.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy Induced Nausea and Vomiting: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Nausea and Vomiting therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Nausea and Vomiting drugs.

Chemotherapy Induced Nausea and Vomiting Report Insights

Chemotherapy Induced Nausea and Vomiting Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chemotherapy Induced Nausea and Vomiting Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chemotherapy Induced Nausea and Vomiting drugs?

How many Chemotherapy Induced Nausea and Vomiting drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Nausea and Vomiting therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chemotherapy Induced Nausea and Vomiting and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Helsinn Healthcare SA

Acacia Pharma

Camurus

Benuvia Therapeutics

Aphios Corporation

Aphios Corporation

Zhuhai Beihai Biotech Co., Ltd.

Key Products

Fosnetupitant

APD403

CAM2047

Ondansetron sublingual

Zindol

Research programme: Cannabinoid Nano therapeutics

BH006